Information Provided By:
Fly News Breaks for October 8, 2015
NBIX
Oct 8, 2015 | 10:58 EDT
Piper Jaffray analyst Charles Duncan said an important potential point of differentiation for Neurocrine's NBI-98854 in tardive dyskinesia is that dosing of the drug did not require titration, as is the case with other drugs in the VMAT2-inhibitor class. The analyst said the new data increases his confidence in the program and raised his price target on Neurocrine shares to $96 from $86.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.